According to Paratek Pharmaceuticals
's latest financial reports the company has a price-to-book ratio of -0.6348.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Year | P/B ratio | Change |
---|---|---|
2022-12-31 | -0.6252 | -64.55% |
2021-12-31 | -1.76 | -36.88% |
2020-12-31 | -2.79 | -30.98% |
2019-12-31 | -4.05 | -216.39% |
2018-12-31 | 3.48 | -42.64% |
2017-12-31 | 6.06 | 24.58% |
2016-12-31 | 4.87 | 47.52% |
2015-12-31 | 3.30 | -43.47% |
2014-12-31 | 5.84 | 561.42% |
2013-12-31 | 0.8825 | 1.29% |
2012-12-31 | 0.8712 | -45.96% |
2011-12-31 | 1.61 | 3.37% |
2010-12-31 | 1.56 | 21.8% |
2009-12-31 | 1.28 | 176.83% |
2008-12-31 | 0.4626 | -72.04% |
2007-12-31 | 1.65 | -23.99% |
2006-12-31 | 2.18 | |
2005-12-31 | N/A | |
2004-12-31 | N/A |
Company | P/B ratio | differencediff. | Country |
---|---|---|---|
Ultragenyx RARE | 13.0 | -2,154.14% | ๐บ๐ธ USA |
Spectrum Pharmaceuticals
SPPI | 7.89 | -1,342.37% | ๐บ๐ธ USA |
Agenus
AGEN | -1.77 | 179.05% | ๐บ๐ธ USA |